

# ABBVIE INC.

ISIN: US00287Y1091 WKN: 00287Y109 Asset Class: **Stock**

**Company** 2024/05/03 22:00:02

**Price**  
**163.79**  
USD

**Difference** ▲ 1.85%(2.98)



**Contact Details**

ABBVIE INC. Tel: +1-847-932-7900  
 -- Fax: +  
 1 North Waukegan Road Web: <http://www.abbvie.com>  
 60064-6400 North Chicago E-mail: -

## Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	33,002,000,000		28,463,000,000		27,928,000,000	
<b>Common stock capital</b>		18,000,000		18,000,000		18,000,000
<b>Fixed assets</b>	101,709,000,000		110,342,000,000		118,601,000,000	
<b>Equity capital of a company</b>		10,397,000,000		17,287,000,000		15,436,000,000
<b>Cash and cash equivalents</b>	12,814,000,000		9,201,000,000		9,746,000,000	
<b>Accrued liabilities</b>		1,538,000,000		1,638,000,000		3,153,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		37,841,000,000		29,538,000,000		35,194,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		86,473,000,000		91,980,000,000		95,899,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		23,373,000,000		21,761,000,000		18,865,000,000
<b>Total assets</b>	134,711,000,000	134,711,000,000	138,805,000,000	138,805,000,000	146,529,000,000	146,529,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	50,000	50,000	50,000
<b>Equity ratio</b>	7.75%	12.48%	10.55%
<b>Debt-equity ratio</b>	1,191.08%	701.41%	847.55%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	22.03%	12.11%	11.09%

# ABBVIE INC.

ISIN: US00287Y1091

WKN: 00287Y109

Asset Class: **Stock**

## Income statement

	2023	2022	2021
Turnover	54,318,000,000	58,054,000,000	56,197,000,000
Net income	4,820,000,000	11,782,000,000	11,468,000,000
EBIT	7,530,117,000	14,590,884,700	14,368,806,900
Operating income before taxes	6,250,000,000	13,477,000,000	12,989,000,000
Cash Flow	22,801,000,000	24,943,000,000	22,777,000,000
Net interest income	-1,820,000,000	-2,160,000,000	-2,410,000,000
Research and development expenses	7,038,000,000	6,487,000,000	6,980,000,000
Income taxes	1,377,000,000	1,632,000,000	1,440,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,013,683	1,083,404	1,048,748

## Board of Directors

## Members of Management Board

Robert Alpern	Member of Board of Directors
Susan Quaggin	Member of Board of Directors
Brett Hart	Member of Board of Directors
Edward Rapp	Member of Board of Directors
Frederick Waddell	Member of Board of Directors
Glenn Tilton	Member of Board of Directors
Jennifer Davis	Member of Board of Directors
Melody Meyer	Member of Board of Directors
Rebecca Roberts	Member of Board of Directors
Roxanne Austin	Member of Board of Directors
Thomas Freyman	Member of Board of Directors
William Burnside	Member of Board of Directors
Richard A. Gonzalez	Chairman of Managing Board
Azita Saleki-Gerhardt	Member of Executive Committee
Jeffrey R. Stewart	Member of Executive Committee
Nicholas Donoghoe	Member of Executive Committee
Perry C. Siatis	Member of Executive Committee
Robert A. Michael	Member of Executive Committee
Scott Reents	Member of Executive Committee
Timothy J. Richmond	Member of Executive Committee